Veterinary & Biosecurity
Mak, Alfasan Sign Anti-Tick Vaccine Production MoU
Makerere University on Friday 19th March, 2021 signed a Memorandum of Understanding (MoU) with Alfasan Uganda Limited to facilitate production of test batches of the Anti-Tick Vaccine developed by the College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB). The MoU was signed on behalf of Makerere University by the Vice Chancellor, Prof. Barnabas Nawangwe and on behalf of Alfasan by the Managing Director Dr. Stephen Birungi. The Principal CoVAB-Prof. John David Kabasa, Anti-Tick Vaccine Initiative Principal Investigator (PI)-Dr. Margaret Saimo-Kahwa and Acting (Ag.) Manager Intellectual Property Management Office (IPMO)-Canon Goddy Muhumuza signed as witnesses.
The Anti-Tick Vaccine Initiative is hosted under the Centre for Biosecurity and Global Health, CoVAB. According to the Prof. Kabasa, the Centre was one of the milestones endorsed by the University when the then faculty to college transition was proposed. “I am happy to report that the Centre is being vigorously supported by the Government to undertake activities of vaccine development together with other scientists.”
He thanked the Vice Chancellor always taking keen interest in the multidisciplinary programmes undertaken by the college with a view improving the livelihoods of both small and large scale livestock farmers. He equally lauded the CoVAB scientists for their efforts to develop the Anti-Tick Vaccine and stakeholders such as the Africa Institute for Strategic Animal Resource Services and Development (AFRISA), Centre of Tropical Medicine and the Ruth Keesling Wildlife Health, Research and Outreach Centre (RK_WHERE) for their support.
Unveiling the research challenge and solution, the PI Dr. Margaret Saimo-Kahwa noted that ticks as vectors for diseases like East Coast Fever are an economic threat to farmers with herds of exotic breeds, their crosses and increasingly, local breeds raised in a tick-free environment. Furthermore, common tick species in Uganda have developed resistance to acaricides used in spraying as a method of their control. This resistance is further exacerbated by acaricide contamination of the environment, leading to residues in animal products like milk and meat, which have implications on human health.
“Therefore, alternative methods like anti-tick vaccines that reduce the use of acaricides are urgently needed to protect the livestock sector that plays a role in poverty reduction and contributes at least 3.2% to Uganda’s GDP, which is equivalent to about 1 Trillion Uganda Shillings” said Dr. Saimo-Kahwa.
The efficacy of any innovation is measured by how well it has worked elsewhere. The Anti-Tick Vaccine Initiative therefore sought inspiration from Australia, where the first anti-tick vaccine was developed in the 1980s as well as Cuba where the vaccines have been used successfully for over 20 years. Gleaning further from Brazil, the team used biotechnology approaches to develop antigens that can target the ticks in Uganda.
“Testing of these molecules under laboratory conditions with funding from the Government of Uganda has been done” remarked the Principal Investigator before adding, “The next step is to test these molecules in clinical trials. However, the molecules should be manufactured under Good Manufacturing Practice (GMP) and not under laboratory conditions.”
Dr. Saimo-Kahwa at this point thanked the President, H.E. Yoweri Kaguta Museveni, whose advice led the research team to the GMP-certified Alfasan Uganda Limited. “These negotiations have been fruitful, leading to the drafting of a memorandum of understanding for production of test batches of the potential vaccine, with funding from Government of Uganda.”
Dr. Stephen Birungi a Makerere University alumnus from CoVAB was all praises for his alma mater and commended Prof. Barnabas Nawangwe for ushering in era of innovation in the short time he has served as Vice Chancellor. “If we are seeing a threat to the livestock industry, we need to act now to save the 20-30% of Uganda’s 15million head of cattle that we lose annually due to tick-borne diseases.”
He reassured all present that Alfasan, a private company certified for the production of veterinary biologicals, was fully committed to improving the livelihood of Ugandan livestock farmers by partnering with the Government of Uganda and institutions such as Makerere University.
“Alfasan as a factory that was born out of partnership between Uganda and Holland is ready to give the facilities that will convert this beautiful innovation from Makerere; once again proving that Makerere is not just a theoretical teaching institution but is ready to bring out those products that can change lives in our country” affirmed Dr. Birungi.
He thanked Makerere University for recognizing the need to produce homegrown vaccines, noting that imported batches tend become less efficacious after multiple applications due to varying protein compositions of the ticks in countries where the remedies originate and Uganda.
“It is therefore important that Government doubles the effort to support CoVAB and Makerere University so that we don’t only stop at this solution but go out and solve even bigger problems using research that has been proven such as this anti-tick vaccine” Dr. Birungi added.
Makerere University is home to a number of innovations, whose number keeps growing thanks to generous funding from the Government and other partners. In recognition of the need to translate these innovations into commercially viable products, the University introduced an Intellectual Property Management Office and appointed Canon Goddy Muhumuza as Ag. Manager. Guiding the MoU signing ceremony, Canon Muhumuza, who also doubles as Principal Legal Officer, made specific mention of the clause on “Ownership” clarifying that Makerere University shall own the patent of the vaccine.
“A new dawn is setting on Makerere University. Makerere University is becoming a truly international research university,” commenced the Vice Chancellor as he made closing remarks following the brief MoU signing and exchange ceremony.
He thanked Dr. Saimo-Kahwa for her great work and mentorship as shown by the constitution of her team, mainly made up of young people. The team is made up of Scientists; Dr. Olaho Mukhani William, Dr. Kokas Ikwap, Dr. Mukiibi Herbert, Dr. Ochwo Sylvester, Dr. Musadha Zachary and Mr. Peregrine Sebulime.
In order to study the life and breeding cycles of ticks, the Initiative included a specialist (Acarologist), Mr. Charles Ssekitto. Technicians who form part of the team include; Mr. Geoffrey Ssentamu, Mr. Nalumenya David, Ms. Namubiru Sarah and Mr. Abubaker Musoba. Mr. Gerald Brooks Musinguzi is in charge of Communication while Ms. Kaudha Rose is the Administrator.
The Vice Chancellor noted that the capacity to develop vaccines was evidence of attaining to the highest levels of research capacity and expressed great pride to learn that the team was completely Ugandan. He thanked the Government of Uganda for the heavily investing in research at Makerere University and reminded staff of their obligation to give back to the taxpayers by providing good accountability.
“I must thank the leadership of the college for the great work they are doing. Professor Kabasa is passionate about Makerere and Uganda and what we should be doing to develop our country” remarked Prof. Nawangwe.
Results from the trials conducted so far showed that the overall efficacy of the vaccine candidate proteins was 86% for R appendiculatas (the brown ear tick) that transmits East Coast Fever (ECF) and 53% for R decoloratus that transmits Babesiosis. “If this vaccine can reduce the burden of tick borne diseases, we will have through one single innovation made a huge contribution to solving one of Uganda’s biggest problems.”
Prof. Nawangwe thanked Alfasan Uganda Limited for being pioneers in implementing academia-private sector collaboration. “As we come up with more innovations and move towards being a research-led University, it is inevitable that we have to work with the private sector, and I thank Managing Director for this gesture… you are a good alumnus.”
This MoU marks the beginning of a long and mutually beneficial partnership between academia and the private sector. The Anti-Tick Vaccine Initiative intends to expand the immunization to include more animals and carry out a clinical trial to determine the appropriate dosage and schedule. Furthermore, the Anti-Tick Vaccine candidate proteins offer more opportunities to include other candidate vaccine proteins of other cattle diseases into the combination.
The event was moderated by the Principal Public Relations Officer, Ms. Ritah Namisango and the Communication Officer CoVAB, Mr. Gerald Brooks Musinguzi.
Article by Public Relations Office
Veterinary & Biosecurity
Prof. Clovice Kankya Assumes Leadership at the College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB)
Prof. Clovice Kankya officially assumed leadership of Makerere University’s College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB) on Thursday, September 17, 2026, taking over from outgoing principal Prof. Frank Norbert Mwiine in a handover ceremony presided over by Chief Human Resources Officer Deus Mujuni.
Upon assuming office, Prof. Clovice Kankya has laid out a six-pillar vision to transform the College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB). The vision focuses on shifting from lecture-based to competence-driven teaching, advancing impactful research that translates into innovation and national development.
Further, he said his leadership will support building valuable partnerships that strengthen staff capacity and global contribution. He emphasized treating people as the greatest resource by addressing staff attrition and fostering mentorship, while reinforcing governance and accountability to ensure institutional trust. Finally, he pledged to create a listening college with open communication channels between staff and students, positioning CoVAB as a hub of excellence, innovation, and impact.
Prof. Clovice Kankya, in his maiden address as Principal CoVAB, began with heartfelt appreciation: “I stand before you with a profound sense of gratitude, humility, and responsibility.” He pledged to confront challenges honestly, build on existing achievements, and transform ideas into measurable outputs. Emphasizing his leadership philosophy, he declared that it is anchored on “continuity where continuity serves, change where change is necessary, and innovation where innovation can create greater impact.”
A Call to Collective Action
Prof. Kankya urged students to challenge the college intellectually and prepare to become solution creators rather than job seekers. He called on staff for active participation and constructive criticism, and encouraged researchers and partners to form multidisciplinary teams tackling Uganda’s pressing problems.
Further, he pledged to lead with consultation, accountability, and consensus-building. “Today marks the beginning of a new chapter. It’s not a chapter that I write alone; it’s a chapter that we shall write together,” he said. “Together, let us move CoVAB from retention to practice, from knowledge to innovation, and from innovation to impact.”
Prof. Kankya envisions CoVAB as a hub of academic excellence, innovation, and impact — with improved infrastructure, digital transformation, enhanced staff development, and financial sustainability. His leadership is expected to strengthen academic programs, enhance resource mobilization, and steer the college toward greater influence in veterinary medicine and animal resources, both in Uganda and beyond.
Legacy of Prof. Frank Norbert Mwiine at CoVAB
Outgoing Principal Prof. Mwiine highlighted milestones during his tenure, including the construction of a 980-million-shilling hostel at Buyana Stock Farm, roofing of the CoVAB building, acquisition of a bus for student transport, provision of 500 lecture hall seats, and painting of the college building without drawing on university funds. Yet, he also pointed to persistent challenges such as staffing gaps, unimplemented departmental restructuring, and high staff attrition. He urged his successor to remain resilient, stressing that resource mobilization often comes with resistance and criticism.
The Chief Human Resources Officer for Makerere University, Mr. Deus Mujuni commended Prof. Mwiine for leaving an indelible mark on the college and urged Prof. Kankya to build on that legacy. He emphasized continuity, urging the new principal to consult past leaders and rely on institutional memory, while reminding staff to extend the same trust and dedication to the incoming leadership.
The Minister for Science, Technology and Innovation, Rt. Hon. Eng. Asiimwe Jonard, visited the College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB) during his maiden official visit to Makerere University, commending the tremendous research work ongoing at CoVAB and across the University.
In his remarks, the Minister noted that his visit to the University highlighted the pivotal role of research, technology, and innovation in shaping Uganda’s economic transformation and showcased Makerere’s capacity to translate groundbreaking scientific discoveries into practical solutions that address both national and global challenges.
The visit, held on September 16th, 2026, was anchored under the theme “Research Infrastructure, Emerging Technologies and Enterprise Creation.” It offered the Minister an opportunity to tour CoVAB’s state-of-the-art facilities at the Centre for Global Biosecurity and Biomolecular Technology (CeBioTech) and engage directly with faculty, researchers, and students. He commended the college for its tremendous contributions to animal health, food security, and biosecurity, emphasizing that these areas are vital to building a resilient and sustainable economy for Uganda.
While addressing college staff, researchers, and other stakeholders, the Minister emphasized that universities must serve as engines of innovation, moving beyond scholarly work to commercialization. He commended CoVAB’s vaccine development for both humans and animals, describing it as a cornerstone of Uganda’s biosecurity agenda. He further highlighted the importance of integrating social sciences into innovation, noting that project management and product development strategies are essential to fast-track research outputs into viable enterprises.
The Minister toured several flagship facilities at CoVAB, including the Central Laboratory Animal Research Facility, which provides laboratory animal services and pre-clinical trial support; RePROVaD, which designs recombinant proteins and subunit vaccines for emerging infectious diseases such as COVID-19 and Mpox; the Anti-Tick Vaccine project, which addresses the persistent challenge of ticks and tick-borne diseases affecting livestock productivity; and BIOMARKER, which develops antibody-based diagnostics to strengthen disease detection. These initiatives, he noted, demonstrate Makerere University’s capacity to contribute meaningfully to both national and global health challenges.
Looking ahead, the Minister outlined priority actions where CoVAB is expected to play a leading role. These include advancing veterinary innovations toward certification and commercialization, leveraging artificial intelligence to strengthen Uganda’s pathogen economy, positioning veterinary science as a driver of agro‑industrialization, developing sustainable models for shared diagnostic and biosecurity laboratories, and providing commercialization support for innovators in areas such as intellectual property, regulation, standards, and market access. By focusing on these areas, he emphasized, CoVAB will not only enhance Uganda’s scientific capacity but also accelerate the country’s journey toward economic resilience and prosperity.
Asiimwe pledged continued support for Makerere University and encouraged the development of structured University–Industry exchange models to ensure veterinary research translates into enterprise creation. He also emphasized the importance of self-sustainability for research centers, noting that revenue generation is key to long-term impact.
The Vice Chancellor, Prof. Barnabas Nawangwe, thanked the Minister for recognizing CoVAB’s strategic role and reaffirmed Makerere’s commitment to advancing veterinary science and innovation for Uganda’s prosperity.
Veterinary & Biosecurity
Parliamentary Committee on Science, Technology and Innovation Reviews Uganda’s Emerging Science Ventures
By Jacinta Nakaye
Uganda’s drive to strengthen science, technology and innovation took center stage as the Parliamentary Committee on Science, Technology and Innovation toured Makerere University’s Centre for Biosecurity and Biomolecular Technology (CeBIOTECH). The centre is hosted at the College of Veterinary Medicine, Animal Resources and Biosecurity (CoVAB). The visit aimed to assess the progress of ventures supported under the Science, Technology and Innovation–Office of the President (STI-OP).
The visit brought legislators, scientists, and innovators together around a shared question: How can Uganda turn investments in scientific research into practical technologies, enterprises, and solutions that respond to national development challenges?
At CeBIOTECH, the Committee was taken through a portfolio of emerging science ventures, including Central Laboratory Animal Research Facility, which focuses on providing lab animal services, pre-clinical trial support, and specialized training to accelerate biosecurity and health solutions; RePROVaD, which focuses on designing and manufacturing recombinant proteins and subunit vaccines for emerging infectious diseases such as COVID-19 and Mpox; the Anti-Tick Vaccine venture focused on addressing the challenge of ticks and tick-borne diseases; and BIOMARKER focused on developing Antibody-based diagnostics.
The delegation also toured laboratories within the Centre where research, product development and other activities supporting the ventures are undertaken.
The engagement offered the Committee a first-hand view of the scientific infrastructure, expertise and processes underpinning Uganda’s efforts to move research beyond academic discovery and towards innovation, enterprise development and eventual application.
Where science meets national priorities
For years, Uganda has invested in research and generated scientific knowledge across universities and research institutions. However, converting that knowledge into products and services that reach communities and markets remains one of the country’s most important innovation challenges. The ventures showcased at CeBIOTECH represent an attempt to bridge this gap.
Although they operate in different areas, the ventures share a common pathway using scientific research and technological expertise to develop solutions with potential to address challenges facing Ugandans while contributing to economic growth.
The Parliamentary Science Committee’s visit consequently provided more than an opportunity to observe ongoing research. It created a platform for legislators to interact with the scientists behind the innovations and gain insight into the journey from research concept to a potentially viable product or enterprise.
That journey can involve years of research, laboratory experimentation, testing, validation, regulatory requirements, intellectual property protection, investment, and commercialisation.
A diverse portfolio of innovation
The diversity of ventures at CeBIOTECH reflects the broad scope of Uganda’s science and innovation agenda.
The CLARF, REPROVaD, and BIOMARKER ventures demonstrate the range of scientific work being pursued. At the same time, the Anti-Tick Vaccine Venture highlights efforts to address one of the persistent challenges affecting livestock production.
Rather than viewing the ventures as isolated projects, the visit highlighted the importance of building an ecosystem in which scientific discoveries can be nurtured into sustainable enterprises.
Such an ecosystem requires more than laboratory facilities. It depends on skilled human resources, research financing, modern infrastructure, regulatory support, partnerships, intellectual property management, manufacturing capacity, and market access.
Taking the fight against ticks beyond conventional control
One of the ventures presented to the Committee was the Tick Control Innovations Initiative Ltd.’s Anti-Tick Vaccine Venture, which is developing a vaccine aimed at controlling ticks and reducing the burden of tick-borne diseases in cattle.
Ticks and tick-borne diseases continue to present significant challenges to livestock production, affecting animal health and productivity and placing additional costs on farmers.
The development of an anti-tick vaccine represents an innovative approach to complement conventional tick-control measures and potentially provide farmers with an additional tool for managing the problem.
The inclusion of the venture among the STI-OP innovations showcased to Parliament demonstrates how scientific research can be directed towards challenges with direct implications for agriculture, livestock production and rural livelihoods.
For Uganda, the significance of such innovations lies not only in the scientific breakthrough itself, but also in the possibility of developing locally generated technologies that can eventually reach farmers and contribute to a more productive livestock sector.
The laboratories behind the innovations
A significant part of the Committee’s programme was the tour of CeBIOTECH’s laboratories. The tour offered members an opportunity to see the facilities where scientific investigations and activities supporting the various ventures are undertaken.
Behind every innovation that eventually reaches the market is a substantial amount of work that is rarely visible to the public: laboratory experiments, sample analysis, quality control, testing, documentation, and validation.
The laboratory visits therefore helped demonstrate that successful innovation requires sustained investment in scientific infrastructure and the people who operate it. For Uganda’s science ventures to mature into viable enterprises, maintaining and strengthening such infrastructure will remain critical.
Parliament and the science agenda
The engagement also highlighted the important role Parliament can play in creating an environment in which scientific innovations can thrive.
While researchers generate knowledge and innovators develop technologies, policy and public investment can determine whether promising innovations receive the support needed to progress.
The Parliamentary Science Committee’s interaction with the ventures therefore provided an opportunity to understand the realities of research and innovation. Such an engagement strengthened the connection between policymakers and scientists, ensuring that decisions concerning science, technology and innovation are informed by the practical experiences of those working within the sector.
A step towards an innovation-driven Uganda
The Parliamentary Committee on Science, Technology, and Innovation’s visit to CeBIOTECH comes at a time when Uganda continues to position science, technology, and innovation as central to national transformation. The ventures visited provide a glimpse into what this ambition can look like in practice; scientists working on locally relevant challenges, laboratories supporting research and development, and emerging enterprises seeking to convert scientific knowledge into usable solutions.
The visit also underscored the importance of sustained collaboration among government, Parliament, universities, research institutions, private-sector players and investors. For the innovators at CeBIOTECH, the engagement provided an opportunity to demonstrate progress, highlight the potential of their work and draw attention to the support required to move their innovations to the next level. For Parliament, it offered a closer look at the people, facilities, and scientific processes behind Uganda’s emerging innovation landscape.
Ultimately, the story unfolding at CeBIOTECH is not simply about laboratories or individual ventures. It is about Uganda’s capacity to generate its own solutions, build enterprises around scientific knowledge, and turn research investment into tangible national value.
As the country pursues a more knowledge-driven economy, the progress of ventures such as CLARF, SUBUNIT, the Anti-Vaccine Venture, RePROVaD, and BIOMARKER will be an important measure of how effectively Uganda can move from research to innovation, from innovation to enterprise, and from enterprise to impact.
-
General2 weeks agoAR Department Bids Farewell to Mr. Ssentongo and Ms. Akoli
-
General7 days agoCall for Applications: RLRH Graduate Traineeship Programme
-
Research2 weeks agoScience Minister Challenges Makerere to Move Research into Use at Scale
-
General2 weeks agoProf. Sarah Ssali shares institutional best practices ahead of The Trust Summit
-
Veterinary & Biosecurity2 weeks agoParliamentary Committee on Science, Technology and Innovation Reviews Uganda’s Emerging Science Ventures